Tag Archives: 15q3

Targeting Trends Newsletter 15q3

Below are links to view the quarterly newsletter Targeting Trends. You can also download the full PDF here. If you would like to be added to the mailing list, please complete the information on our contact page. SP-SAP Human Clinical Trial for Cancer Pain is the cover article this quarter discussing the positive feedback from current […]

Targeting Tools: Beta Products. Great Opportunity for Discovery at a Very Low Price.

Saporin conjugates specifically eliminate cells identified by an extracellular marker. Each week we release new products for beta testing, so check out the website frequently. There are two conjugate configurations for Beta products. The first is a direct conjugate of the targeting agent to saporin; the second is a bonded toxin between the targeting agent […]

Targeting Talk: in vitro cytotoxicity assays

Q: For in vitro cytotoxicity assays, could you tell me: 1) whether you incubate primary with your Saporin secondary for a specific amount of time prior to cell addition, and 2) do you use a single concentration of secondary per well or a primary:secondary ratio — like 1:2 or 1:4? A: The primary antibody should […]

Targeting Talk: Using Kit Controls

Q: Your targeted toxin kits come with different controls. I’m not sure of the best way to use them; there is included unconjugated antibody, unconjugated saporin, and a control conjugate, mouse IgG-SAP. Should I use them all in the same experiment or for different purposes? A: For mouse IgG-containing conjugates, the ideal control is Mouse […]

Targeting Topics 15q3

Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome. Xu M, Kobets A, Du JC, Lennington J, Li L, Banasr M, Duman RS, Vaccarino FM, DiLeone RJ, Pittenger C. Proc Natl Acad Sci U S A 112(3):893-898, 2015. Postmortem studies of Tourette syndrome patients has revealed a reduction in […]

Cover Article: SP-SAP Human Clinical Trial for Cancer Pain – An Anesthesiologist’s Point of View

by Carl Noe, M.D., Anesthesiology & Pain Management, UT Southwestern Medical Center, Dallas, TX; and Eugene McDermott Center for Pain Management, Dallas, Texas Dr. Noe is the Principal Investigator in the ongoing trial of SP-SAP Intrathecal SP-SAP (Substance P attached to the ribosome-inactivating protein, saporin) has been studied in a Phase 1 clinical trial of […]